The Federal Medical Biological Agency of Russia has initiated comparative clinical studies of Hydroxychloroquine, Mefloquine and a Russian-manufactured drug Kalidavir®. These drugs are supposed to be used for therapeutic reasons to treat patients with a new coronavirus disease caused by SARS-CoV-2.
It is planned to compare three groups of patients diagnosed with coronavirus disease caused by SARS-CoV-2 with different severity that will be admitted to the State Research Center Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency of Russia.
Being the only pharmaceutical company in Russia that produces an anti-retroviral drug Kalidavir®, JSC Pharmasyntez is paying close attention to the clinical study results and hopes the test drug Kalidavir® will be found highly effective against SARS-CoV-2.